Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609804 · ClinicalTrials.gov registry record · Phase 2
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00609804 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 53 participants.
The verdict
NCT00609804, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.
Interventions
- DRUG Sorafenib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00609804
The ClinicalTrials.gov registry entry for NCT00609804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00609804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00609804 about?
NCT00609804 is a clinical study titled "Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib". This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.
What is the current status of trial NCT00609804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2008-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00609804?
The interventions under investigation include: Sorafenib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00609804?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.